Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cibinetide - Araim Pharmaceuticals

Drug Profile

Cibinetide - Araim Pharmaceuticals

Alternative Names: ARA 290

Latest Information Update: 05 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Araim Pharmaceuticals
  • Developer Araim Pharmaceuticals; Karolinska Institute; National Institute on Aging; Queens University Belfast
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Peptides
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis; Neuropathic pain; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Diabetic macular oedema; Diabetic neuropathies; Neuropathic pain; Rheumatoid arthritis
  • Phase I Diabetic nephropathies; Non-alcoholic steatohepatitis
  • Preclinical Inflammatory bowel diseases; Retinal disorders; Systemic lupus erythematosus; Transplant rejection; Wounds
  • No development reported Radiation injuries
  • Discontinued Depressive disorders; Type 2 diabetes mellitus

Most Recent Events

  • 05 Apr 2019 Interim pharmacodynamics data from a preclinical trial in retinal disorders released by Araim Pharmaceuticals
  • 04 Apr 2019 Discontinued - Phase-II for Depressive disorders (In volunteers) in Netherlands (IV)
  • 04 Apr 2019 Discontinued - Phase-II for Type 2 diabetes mellitus in Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top